MNKD
MANNKIND CORP
Key Financials
Operating Income
$38.8M
↓ 46.5%
EPS (Diluted)
$0.02
↓ 80.0%
Total Assets
$792.2M
↑ 101.1%
Revenue
$349.0M
↑ 22.2%
Total Liabilities
$843.2M
↑ 78.4%
Shareholders' Equity
$-51022000.00
↑ 35.3%
Cash & Equivalents
$74.9M
↑ 61.6%
Long-term Debt
$354.6M
↑ 883.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/2/2026 | View on SEC |
| 8-K | 5/28/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MNKD |
| Company Name | MANNKIND CORP |
| CIK | 899460 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 818-661-5000 |